Equity Profile

ABT

Abbott Laboratories

Health CareHealth Care Equipment$155.3B

Jul16Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Abbott Laboratories (ABT) is a global healthcare company that develops and manufactures a wide range of medical devices, diagnostics, and nutritional products. With a market cap of $155 billion, Abbott plays a crucial role in the health care sector, focusing on innovative solutions that improve patient outcomes and enhance quality of life.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Abbott is managing costs and generating income.

$1.28

Revenue

Revenue growth reflects the company's ability to sell its products and services, which is vital for sustaining operations and investment.

$12.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+1.05%

Avg Stock Reaction

-3.34%

Last Quarter Recap

In Q1-2026, Abbott reported an EPS of $1.15, slightly beating estimates. However, the stock dropped 6% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Abbott to report solid earnings this quarter, with consensus estimates indicating a slight increase in EPS and revenue. However, investor sentiment may be cautious given recent stock performance.

Bull Case

If Abbott can exceed the EPS estimate of $1.28, it may signal strong demand for its products and lead to a positive stock reaction.

Bear Case

On the other hand, if Abbott fails to meet expectations or provides weak guidance, it could raise concerns about future growth and lead to a further decline in the stock.

Key Metrics to Watch

EPS

$1.28

Earnings per share is a key indicator of profitability and will show how well Abbott is managing costs and generating income.

Revenue

$12.5B

Revenue growth reflects the company's ability to sell its products and services, which is vital for sustaining operations and investment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Abbott's EPS exceed the consensus estimate of $1.28?

A strong EPS report could indicate robust demand and effective cost management, which are critical for investor confidence.

What guidance will Abbott provide for future revenue growth?

Future revenue guidance will be crucial for assessing the company's growth trajectory and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Abbott's ability to leverage its diverse product portfolio, particularly in diagnostics and nutrition, which could drive stronger-than-expected revenue growth.

Supporting Evidence

Abbott has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

The options market is pricing a larger move than historical averages, suggesting that investors are anticipating significant news.

Recent insider activity shows no significant selling pressure, which could indicate confidence in future performance.

Key Risk

If Abbott's revenue growth exceeds $12.5 billion, it could challenge the current bearish sentiment and shift market perception.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Abbott's ability to sustain growth amid competitive pressures and recent stock performance.

Bull Confirmed If

An EPS of $1.30 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.26 would raise concerns about Abbott's growth prospects and could lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±8.67%

Historical Avg

±4.6%

Pricing rich

The options market is pricing in a significant move for Abbott's stock following the earnings report, suggesting heightened uncertainty among investors.

Options are pricing ±8.7% while ABT has averaged ±4.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

26.1%

Calls (760K)P/C Ratio: 0.51Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Abbott beats expectations, history suggests the stock could rise by around 4.62% on the first day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors assess management's commentary.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of around 3.34% following such outcomes.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·3 sells

Members

House only

Est. Notional

$6,006.00–$90,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in diagnostics or nutrition.
2Comments on market demand trends in key segments.
3Insights into cost management strategies and their impact on margins.
4Guidance on future revenue growth and market conditions.
5Responses to competitive pressures in the health care equipment sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Fastenal Company

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Abbott is managing costs and generating income.

$1.28

Revenue

Revenue growth reflects the company's ability to sell its products and services, which is vital for sustaining operations and investment.

$12.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+1.05%

Avg Stock Reaction

-3.34%

Last Quarter Recap

In Q1-2026, Abbott reported an EPS of $1.15, slightly beating estimates. However, the stock dropped 6% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Abbott can exceed the EPS estimate of $1.28, it may signal strong demand for its products and lead to a positive stock reaction.

Bear Case

On the other hand, if Abbott fails to meet expectations or provides weak guidance, it could raise concerns about future growth and lead to a further decline in the stock.

Key Metrics to Watch

EPS

$1.28

Earnings per share is a key indicator of profitability and will show how well Abbott is managing costs and generating income.

Revenue

$12.5B

Revenue growth reflects the company's ability to sell its products and services, which is vital for sustaining operations and investment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Abbott's EPS exceed the consensus estimate of $1.28?

A strong EPS report could indicate robust demand and effective cost management, which are critical for investor confidence.

What guidance will Abbott provide for future revenue growth?

Future revenue guidance will be crucial for assessing the company's growth trajectory and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Abbott's ability to leverage its diverse product portfolio, particularly in diagnostics and nutrition, which could drive stronger-than-expected revenue growth.

Supporting Evidence

Abbott has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

The options market is pricing a larger move than historical averages, suggesting that investors are anticipating significant news.

Recent insider activity shows no significant selling pressure, which could indicate confidence in future performance.

Key Risk

If Abbott's revenue growth exceeds $12.5 billion, it could challenge the current bearish sentiment and shift market perception.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Abbott's ability to sustain growth amid competitive pressures and recent stock performance.

Bull Confirmed If

An EPS of $1.30 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.26 would raise concerns about Abbott's growth prospects and could lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±8.67%

Historical Avg

±4.6%

Pricing rich

The options market is pricing in a significant move for Abbott's stock following the earnings report, suggesting heightened uncertainty among investors.

Options are pricing ±8.7% while ABT has averaged ±4.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

26.1%

Calls (760K)P/C Ratio: 0.51Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Abbott beats expectations, history suggests the stock could rise by around 4.62% on the first day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors assess management's commentary.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of around 3.34% following such outcomes.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·3 sells

Members

House only

Est. Notional

$6,006.00–$90,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in diagnostics or nutrition.
2Comments on market demand trends in key segments.
3Insights into cost management strategies and their impact on margins.
4Guidance on future revenue growth and market conditions.
5Responses to competitive pressures in the health care equipment sector.